Niagen Bioscience Inc.

Last updated September 27, 2026

Organization details

Legal name
Niagen Bioscience Inc.
Ownership
Public
Status
Active
Headquarters country
United States
Ticker symbol
NAGE
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001386570

Board of directors

Chief executives

Robert N. Fried · Chief Executive Officer
Dates unknown

Board connections

2 of this board's directors also sit on 5 other boards.

Network of Niagen Bioscience Inc.'s board connections Cocrystal Pharma Inc. Cocrystal Pharma Inc. Eloxx Pharmaceuticals Inc. Eloxx Pharmaceuticals... OPKO Health Inc. OPKO Health Inc. Red Violet Inc. Red Violet Inc. Super League Enterprise Inc. Super League Enterpris... Kristin Patrick Kristin Patrick Steven D. Rubin Steven D. Rubin Niagen Bioscience Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Dec 13, 2024 Frank L. Jaksch Jr. Director Option exercise +50,001 $3.66 $183,004
Dec 13, 2024 Frank L. Jaksch Jr. Director Open-market sale −37,161 $6.19 $230,027
Nov 22, 2024 Pamir Ozan Officer (Chief Financial Officer) Open-market purchase +2,907 $7.36 $21,397
Aug 23, 2024 Kristin Patrick Director Option exercise +3,000 $1.64 $4,920
Aug 23, 2024 Kristin Patrick Director Option exercise +20,000 $1.67 $33,400
Aug 23, 2024 Kristin Patrick Director Open-market sale −23,000 $3.57 $82,110
Aug 20, 2024 Li Ka Shing 10% owner Open-market sale −11,408,715 — —
Aug 20, 2024 Winsave Resources Ltd 10% owner Open-market purchase +11,408,715 — —
Dec 1, 2023 Gerber Brianna Officer (Chief Financial Officer) Open-market purchase +5,000 $1.41 $7,050
Sep 6, 2023 Champion River Ventures Ltd Director, 10% owner Open-market purchase +3,467,778 — —
Aug 12, 2023 Gerber Brianna Officer (Chief Financial Officer) Option exercise +22,436 — —
Jun 12, 2023 Frank L. Jaksch Jr. Director Open-market purchase +7,000 $1.69 $11,830
May 31, 2023 Robert N. Fried Director, Officer (Chief Executive Officer) Open-market purchase +7,000 $1.42 $9,940
May 25, 2023 Steven D. Rubin Director Open-market purchase +7,000 $1.46 $10,220

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.